The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019 Miscellaneous


Authors: Ascierto, P. A.; Agarwala, S. S.; Eggermont, A.; Gershenwald, J. E.; Grob, J. J.; Hamid, O.; Michielin, O.; Postow, M.; Puzanov, I.; Zarour, H. M.; Caracò, C.; Testori, A.
Title: The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019
Abstract: The Great Debate session at the 2019 Melanoma Bridge congress (December 5-7, Naples, Italy) featured counterpoint views from experts on five topical issues in melanoma. These were whether to choose local intratumoral treatment or systemic treatment, whether patients with stage IIIA melanoma require adjuvant therapy or not, whether treatment is better changed at disease progression or during stable disease, whether adoptive cell transfer (ACT) therapy is more appropriate used before or in combination with checkpoint inhibition therapy, and whether treatment can be stopped while the patient is still on response. As was the case for previous meetings, the debates were assigned by meeting Chairs. As such, positions taken by each of the melanoma experts during the debates may not have reflected their respective personal approach.
Keywords: melanoma; targeted therapy; neoadjuvant; adjuvant; anti-ctla-4; mek inhibitor; braf inhibitor; anti-pd-1; staging immunotherapy
Journal Title: Journal of Translational Medicine
Volume: 18
ISSN: 1479-5876
Publisher: Biomed Central Ltd  
Date Published: 2020-01-01
Start Page: 171
Language: English
DOI: 10.1186/s12967-020-02340-w
PUBMED: 32299446
PROVIDER: scopus
PMCID: PMC7164218
DOI/URL:
Notes: Article -- Export Date: 1 May 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael Andrew Postow
    362 Postow